ArticleEuropean radiology2026
Enhancing Node-RADS for preoperative assessment of cervical lymph node metastases in papillary thyroid carcinoma: validation and modification.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic and Diagnostic Value of Node-RADS for Non-Small Cell Lung Cancer Following Neoadjuvant Therapy: A Multicenter Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
objectivesTo evaluate the diagnostic performance of the Node Reporting and Data System (Node-RADS) and its enhanced versions for central (CLNM) and lateral lymph node metastases (LLNM) in papillary thyroid cancer (PTC). MATERIALS AND
methodsThis retrospective study enrolled 227 patients with histologically confirmed PTC who underwent preoperative thyroid-dedicated contrast-enhanced CT. The original Node-RADS scores were assigned to lymph nodes in cervical levels II-VI, and the results were compared with histopathology. A Hyper‑Enhancement Node‑RADS (HE‑Node‑RADS) model by assigning a hyper‑enhancement feature was further developed. Multivariate logistic regression was used to identify independent predictors of CLNM and construct a Nomogram‑Augmented Node‑RADS (NA‑Node‑RADS). The diagnostic performance of different thresholds of Node-RADS and the modified models was assessed and compared.
resultsNode-RADS demonstrated moderate to good diagnostic performance for both CLNM (threshold > 1, AUC = 0.741) and LLNM (threshold > 2, AUC = 0.801). Interobserver agreements were excellent (κ = 0.838 for CLNM and κ = 0.827 for LLNM). At threshold > 2, HE-Node-RADS (AUC = 0.883) was significantly superior to Node-RADS for LLNM (p = 0.004). NA-Node-RADS (predicted probability > 47.1%), incorporating age, sex, primary tumor size, and core node features (texture, border, shape), showed superior predictive power for CLNM (AUC = 0.879) compared to Node-RADS (0.795) and HE-Node-RADS (0.807), with good calibration and superior net benefit on decision curve analysis.
conclusionCT‑based Node‑RADS offered robust LNM assessment in PTC. The addition of hyper-enhancement improves Node-RADS performance for LLNM, and the proposed nomogram based on Node-RADS further refines CLNM risk estimation. KEY POINTS: Question How about the Node-RADS for lymph node metastasis (LNM) assessment in papillary thyroid cancer (PTC), and can it be improved? Findings Node-RADS demonstrates moderate to good diagnostic efficacy. Hyper‑enhancement Node‑RADS and Nomogram‑Augmented Node‑RADS are significantly superior for lateral and central LNM, respectively. Clinical relevance Node‑RADS is useful for preoperative assessment of LNM in PTC, but thresholds vary by neck compartment. Integrating hyper-enhancement enhances lateral Node-RADS performance, while incorporating clinical factors improves central Node-RADS and may facilitate individualized clinical decision-making.
Indexed as
Identifiers
41748926What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.